. Author manuscript; available in PMC: 2024 Mar 1.

Published in final edited form as: Pediatr Pulmonol. 2022 Dec 9;58(3):825–833. doi: 10.1002/ppul.26261

Table 1.

Changes in clinical outcomes over time for pwCF receiving ETI.

	Baseline⁵	3 months	6 months	9 months	12 months
	Mean ±SD
%FEV1 ¹	63±27	71±27	73±26	72±26	68±28
% change²		12.7%	15.9%	14.3%	7.9%
P		<0.001^*	<0.001^*	<0.001^*	<0.001^*
BMI ¹	22.5±4.6	23.5±4.2	23.8±4.3	23.7±4	24±4.2
% change²		4.4%	5.8%	5.3%	6.7%
p		<0.001^*	<0.001^*	<0.001^*	<0.001^*
+ *Pseudomonas*³
N	48	48	46	39	40
n (%)	25 (52.1%)	15 (31.3%)	15 (32.6%)	9 (23.1%)	10 (25%)
% change⁴		−40%	−37.4%	−55.7%	−52%
p		0.008^*	0.007^*	0.001^*	<0.001^*
+ MRSA³
N	48	48	46	39	40
n (%)	21 (43.8%)	15 (31.3%)	14 (30.4%)	11 (28.2%)	11 (27.5%)
% change⁴		−28.5%	−30.6%	−35.6%	−37.2%
p		0.034^*	0.059	0.096	0.003^*

Paired t-test

Percent change in %FEV1 and BMI compared to baseline was calculated as (Mean at 3-, 6-, 9-, or 12 months - Mean at baseline) / (Mean at baseline) × 100%

Wilcoxin signed rank test

⁴

Percent change (increase or decrease) in Pseudomonas and MRSA compared to baseline was calculated as (% at 3-, 6-, 9-, or 12 months - % at baseline) / (% at baseline) × 100%

⁵

(n=15) with flow cytometry analysis average baseline FEV1 52±23.3, BMI 21.8±4.1, 68% +Pseudomonas, 53% +MRSA

p≤ 0.05